

1653  
TFu

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Rouli ZHOU *et al.*

U.S. Application No. 10/540,539

National Stage of: PCT/CN2003/001109  
under 35 U.S.C. §371

Art Unit: Not Assigned

International Filing Date: December 24, 2003

Examiner: Not assigned

For: HUMAN CANCER-RELATING  
GENES, THE PRODUCTS ENCODED  
THEREBY AND APPLICATIONS  
THEREOF

Attorney Docket No.: 062331-5002

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.56 AND 1.97**

Commissioner for Patents  
U.S. Patent and Trademark Office  
401 Dulany Street  
Alexandria, VA 22314

Sir:


In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to References A01, B01-B06 and C01-C09, cited on the attached Revised PTO Form 1449. These references were cited in the attached Supplementary European Search Report that was mailed to Applicants on March 28, 2006 in the corresponding European application.

Identification of the listed reference is not to be construed as an admission of Applicants or Attorneys for Applicants that the references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since this form identifies all of the references therein as "Prior Art." As an alternative, Applicants submit herewith a "revised PTO Form 1449" entitled "List of References Cited By Applicant" instead of "List of Prior Art Cited."

Applicants respectfully request that the Examiner review these references and make them of record in the present application by signing and returning the enclosed List of References Cited.

No fee is believed to be due for this submission as the references submitted herein are being submitted before the first office action on the merits. However, should the Patent Office determine otherwise, please charge the required fee to Morgan, Lewis & Bockius LLP Deposit Account 50-0310.

Respectfully submitted,


A handwritten signature in black ink, appearing to read 'D. L. Fanelli', written over a horizontal line.

Dean L. Fanelli  
Reg. No. 48,907

Date: August 10, 2006

**MORGAN, LEWIS & BOCKIUS LLP**  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
(202) 739-3000-phone  
(202) 739-3001-fax  
**Customer No.: 009629**

**LIST OF REFERENCES CITED BY APPLICANT**  
(Revised PTO Form 1449)



ATTY DOCKET NO.	APPLICATION NO
062331-5002-US	10/540,539 National Stage of PCT/CN2003/001109
APPLICANT	
R. ZHOU	
FILING DATE	GROUP
December 24, 2003	To Be Assigned

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
A01	6,465,620	10/15/2002	B. Boyle et al.			

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
B01	WO 00/05367	02/03/2000	PCT			
B02	WO 01/12662 A2	02/22/2001	PCT			
B03	WO 01/53312 A1	7/26/2001	PCT			
B04	WO 02/059260 A1	8/01/2002	PCT			
B05	WO 2005/044990A2	05/19/2005	PCT			
B06	WO 2005/032495 A2	04/14/2005	PCT			
B07						

**OTHER REFERENCES** (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Gen-Ze SHAO <i>et al.</i> , Molecular cloning and characterization of <i>LAPTM4B</i> , a novel gene upregulated in hepatocellular carcinoma, 2003, pages 5060-5069.
C02	Mammalian Gene Collection (MGC) Program Team, Strausberg <i>et al.</i> , Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences, Proceedings of the National Academy of Sciences of the U.S.A., December 24, 2002, Vol. 99 No.26. pages 16899-16903.
C03	Grit KASPER <i>et al.</i> , The human LAPTM4b transcript is upregulated in various types of solid tumours an seems to play a dual functional role during tumor progression, Cancer Letters August 8, 2004, Vol. 224, No. 1, pages 93-103.
C04	Database Geneseq [Online] 22 October 2001, Human Polypeptide SEQ ID NO: 2720. XP002372228, retrieved from EBI accession number GSP:AAM39575, Database accession no. AAM39575
C05	Database Geneseq [Online] 22 October 2001, Human Polypeptide SEQ ID NO: 2720. XP002372229, retrieved from EBI accession number GSP:AAI58731, Database accession no. AAI58731
C06	Database EMBL [Online] 30 October 2001, Homo Sapiens Lysosomal Associated Transmembrane Protein 4 Beta, Variant 1 (LAPTM4B) mRNA, complete cds." XP002372230, retrieved from EBI accession number EM_HUM:AY057051, Database accession no. AY057051.
C07	Database EMBL [Online] 1 November 2002, Homo Sapiens Lysosomal Associated Protein Transmembrane 4 Beta, mRNA (cDNA clone MGC:43257 IMAGE:5264567), complete cds." XP002372231, retrieved from EBI accession number EM_HUM:BC038117, Database accession no. BC038117.
C08	Database Geneseq [Online] 25 February 2003, Human Protein SEQ ID NO: 364. XP002372232, retrieved from EBI accession number GSP:ABP64704, Database accession no. ABP64704.
C09	Database EMBL [Online] 1 March 2001, Homo Sapiens Genomic DNA, chromosome 8q23, clone: KB1907C4." XP002372233, retrieved from EBI accession number EM_HUM:AP003357, Database accession no. AP003357.
C10	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.